RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All CDSCO (India) updates
CDSCO (India)
REGULATION
2026.08.14 G.S.R. 744(E)_Amendment in MD Rules, 2017 for inclusion of EU countries in Rule 63 & QMS requirements for Class A NSNM
Published: 8/14/2026Detected: 9/4/2026

Summary preview

Amends India’s Drugs and Cosmetics Rules, 2017 to incorporate EU countries within the scope of Rule 63 and extends/aligns Quality Management System (QMS) expectations for Class A non-sterile non-systemic (NSNM) drug…

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
rare_diseases
immunology
infectious_disease
manufacturing
quality
#CDSCO
#Drugs and Cosmetics Rules 2017
#Rule 63
#EU countries
#QMS

Official Source Document
Source Verified

Access the original document directly from INDIA CDSCO.

View Official Document

More from CDSCO (India)

  • Indiscriminate use of painkillers (NSAIDs), antibiotics and associated risk of Chronic Kidney Disease9/22/2026
  • LIST OF REGISTRED BA-BE STUDY CENTRE & BIO-ANALYTICAL LABORATORY under NDCT Rules 20199/18/2026
  • Public Health alert against the use of unauthorised Cosmetics Products9/14/2026
  • 2026.09.08 G.S.R. 791(E)_Draft notification for amendment in the Drugs Rules 1945 regarding mandatory installation of CCTV surveillance system at sales premises9/8/2026
  • Drug Regulatory and Law Enforcement Agencies Intensify Coordinated Action Against Illegal Manufacture and Distribution of Misbranded Drugs9/5/2026

Get CDSCO (India) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.